Trials / Completed
CompletedNCT04856774
Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
A Multicenter, Open-Label, Phase Ib/II Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study was to assess the safety, tolerability, and efficacy when combining SHR-1701 and BP102 in participants with certain cancers. This study was conducted in 2 phases, Phase Ib and Phase II.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701；BP102 | Drug: SHR-1701 IV infusion Drug: BP102 IV infusion Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined. |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2024-03-30
- Completion
- 2024-03-30
- First posted
- 2021-04-23
- Last updated
- 2024-06-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04856774. Inclusion in this directory is not an endorsement.